Read the First Edition of The Lens, a new magazine by LSI arrow-icon
Published January 2015 | Forecasts through 2019
Global Opportunities in the Interventional Management of Symptomatic Peripheral Artery Disease
Reports Graph
Overview

This report covers the novel drug-coated balloon and drug-eluting stent technologies that are expected to trigger a paradigm shift in treatment of advanced peripheral artery disease-particularly lower extremity occlusions-driving the development of a new multi-billion dollar market. Also covered in the report are revascularization-enabling peripheral atherectomy systems and dedicated refractory CTO crossing devices that are projected to see above-average growth through 2019.

Buy Global Opportunities in the Interventional Management of Symptomatic Peripheral Artery Disease
Companies Covered

Aachen Resonance

Abbott Vascular (Abbott Laboratories) 

Avinger Medical Technologies

Bard Peripheral (C.R. Bard)

Bayer HealthCare (Bayer AG)

Biosensors International

Biotronik 

Boston Scientific

Cardionovum

Cardiovascular Systems 

Cook Medical

Cordis (Johnson & Johnson)

Covidien

Eurocor (Opto Circuits) 

iVascular 

Medtronic

Medtronic plc 

Spectranetics

Order individually or subscribe and
get a complete intel platform.

Trusted By The Companies Pioneering What’s Next